Navigation Links
Medicago succesfully expresses VLP antigen for A H1N1 strain
Date:5/12/2009

QUEBEC CITY, May 12 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has successfully expressed a new VLP antigen ("H1 VLP") from the influenza A (H1N1) strain that caused the recent Influenza outbreak in North America and other countries. The antigen was expressed within 14 days of receiving the DNA sequence with the Company's VLP vaccine technology and Proficia(TM) manufacturing technology.

Initial results show that the new H1 VLP is comparable to other VLPs recently expressed by Medicago such as the New Caledonia strain (H1N1) and Brisbane strain (H1N1). The primary goal of this initiative was to confirm, in a real case-scenario, Medicago's initial development timelines. Medicago requires the genetic sequence of the virus, limiting delays that may happen with traditional systems. The H1 VLP will be purified in preparation for an immunogenicity study in mice. The Company expects results from this study in June, with the goal of confirming the immunogenic potential of this H1 VLP.

"We are thrilled with these initial results. They demonstrate that we can rapidly express an antigen from a new influenza strain without modifying our current technology and could potentially be a first responder solution in the face of a pandemic," said Louis-Philippe Vezina, Chief Scientific Officer of Medicago. "Our ultimate goal is to provide a rapid approach to vaccine production allowing for immediate access to the antigens of emerging influenza strains. Current influenza vaccine manufacturing technologies can take up to six months to produce a vaccine for a new strain. With our proprietary technology we believe we can potentially cut development time up to five months."

About Medicago

Medicago is committed to provide highly effective
'/>"/>

SOURCE Medicago Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Medicago initiates work on Swine Flu strain
2. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
3. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
4. Antigen Discovery Inc. Awarded a SBIR Phase II Grant to Commercialize Novel Antigens for Serodiagnostic Products and Vaccine Development
5. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
6. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
7. Scientists develop strategy to rapidly describe outbreak strains with next-generation DNA sequencing
8. Stretching silicon: A new method to measure how strain affects semiconductors
9. NIST stress tests probe nanoscale strains in materials
10. Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain
11. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Mass. , July 30, 2014 /PRNewswire/ ... ), a biotechnology company focused on discovering, ... unmet medical needs using RNA-targeted technologies, today ... (RXI-109-1402) with RXI-109, for the reduction of ... revision surgery, has been initiated. ...
(Date:7/30/2014)... Diego, CA (PRWEB) July 30, 2014 ... contract from the U.S. Environmental Protection Agency (EPA). ... expertise in developmental toxicity models, including tests designed ... neuron formation and the formation of connections between ... Inhibition of neurodifferentiation and synapse formation by environmental ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LayerBio, Inc., ... completion of its first round of seed financing from ... enable preliminary efforts to develop a novel sustained-release product ... of our investors and their commitment to this important ... LayerBio. "Ophthalmology is one of many areas in which ...
(Date:7/29/2014)... hurdled a number of significant technological challenges in ... technology originally created for the James Webb Space ... Harvey Moseley, a scientist at NASA,s Goddard Space ... electrostatically actuated microshutter arrays that is, those ... as functional as the current technology,s magnetically activated ...
Breaking Biology Technology:RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4
... 30 Rib-X Pharmaceuticals, Inc., a development stage company focused ... treatment of antibiotic resistant infections, announced today that Russell Greig, ... the Company,s Board of Directors. Rib-X,s board now consists ... pleased that Russell Greig has joined the Rib-X Board of ...
... ... Northern Irish packaging machinery manufacturer, Sepha Ltd. is breaking into one of ... testing and de-blistering machines for the first time there ... Ahead of its presence at Interphex, Sepha has already received ...
... /PRNewswire-Asia/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL ),today ... Plan which,closed on 24 June 2009. Shareholders of the ... of shares each at the $2.35 price,paid by institutional investors ... total of 1,584 shareholders participated in the plan under which ...
Cached Biology Technology:Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors 2Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors 3Asia Debut for Money-Saving Pharma-Packaging Machines from Ireland 2Asia Debut for Money-Saving Pharma-Packaging Machines from Ireland 3Pharmaxis Closes Share Purchase Plan 2
(Date:7/30/2014)... could be as simple as inserting a medicated, disappearing ... Washington bioengineers have discovered a potentially faster way to ... HIV. Their method spins the drug into silk-like fibers ... higher doses of the drug than possible with other ... could offer women a potentially more effective, discreet way ...
(Date:7/30/2014)... figured out how to create colors, nature had already ... of many different hues, for example. Now scientists are ... friendly way to make colored plastics. Their paper on ... materials rather than dyes, to produce color appears ... N. Asger Mortensen, Anders Kristensen and colleagues point out ...
(Date:7/30/2014)... awarded the Scientific Committee on Antarctic Research,s (SCAR) ... SCAR, an inter-disciplinary international science body, initiates, develops ... the Antarctic region, and on the role of ... organisation also provides scientific advice about Antarctica to ... region. , The medal is open internationally to ...
Breaking Biology News(10 mins):Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3
... CORVALLIS, Ore. An international group of more than 30 ... their contribution to the health of the world,s oceans, which ... identified food provision, tourism and recreation as leading concerns. ... each nation on a 0-100 scale in 10 separate categories ...
... on fetal growth have consistently demonstrated deficits that persist ... human studies have been inconsistent. A new study ... on growth and body composition throughout childhood has found ... age, as well as a delay in weight gain ...
... cells has provided scientists at Dana-Farber Cancer Institute and the ... entirely new class of genes that may serve as an ... in the Aug. 17 issue of the journal Cell ... of which had previously been identified as potential targets for ...
Cached Biology News:Rating of ocean health shows 'room for improvement' 2Tracking the effects of prenatal alcohol exposure through to 9 years of age 2Tracking the effects of prenatal alcohol exposure through to 9 years of age 3'CYCLOPS' genes may serve as an Achilles' heel in tumor cells 2'CYCLOPS' genes may serve as an Achilles' heel in tumor cells 3
... is most widely used in combination ... differentially stain nucleic acids following polyacrylamide ... solution, Pyronin Y stains RNA red, ... Chem comp: Dye content ...
... The loxP-cm-loxP cassette is ... prokaryotic cells. The prokaryotic promoter ... resistance is a slightly modified version ... higher transcription efficiency than the generally ...
... Agencourt AMPure is a ... that requires no sample transfer, ... efficiently purifies small and large ... or 384-well microplates. Agencourt AMPure ...
... is a magnetic bead-based PCR ... sample transfer, centrifugation or filtration ... and large PCR extension products ... Agencourt AMPure can easily be ...
Biology Products: